

NICE Technology Appraisals About Medicines: Formulary Adherence Checklist



Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

This spreadsheet enables self-audit of a medicines formulary for adherence to NICE Technology Appraisals. No copyright is asserted if used for non-commercial purposes within the NHS.

Technology appraisal (TA)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
2011-12							
Atrial fibrillation - dabigatran etexilate (TA249)	31/03/2012	Dabigatran – a recommended option for atrial fibrillation patients with risk factors to prevent stroke and embolism.	x		15/05/2012	45	To be used in conjunction with SLCSN guideline
Rheumatoid arthritis - tocilizumab (TA247) Update to TA198	29/02/2012	Tocilizumab (with methotrexate) – a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated.	x		20/03/2012	20	
Diabetes (type 2) - exenatide (prolonged release) (TA248)	29/02/2012	Exenatide prolonged release – a recommended option in combination with oral drugs for selected patients with type 2 diabetes	x		20/03/2012	20	
Venom anaphylaxis - immunotherapy pharmlagen (TA246)	29/02/2012	Pharmlagen – a recommended treatment for bee or wasp venom allergy after a severe reaction, or moderate reaction in certain circumstances.	x		20/03/2012	20	
Venous thromboembolism (hip and knee surgery) - apixaban (TA245)	31/01/2012	Apixaban – a recommended option to reduce thromboembolism after knee/hip replacement.	x		21/02/2012	21	
Chronic obstructive pulmonary disease - roflumilast (TA244)	31/01/2012	Roflumilast – only recommended as part of a clinical trial.	x		21/02/2012	21	
Follicular lymphoma - rituximab (TA243) Update to TA110	31/01/2012	Rituximab – recommended in combination for first line treatment of stage III–IV disease.	x		21/02/2012	21	
Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)	31/01/2012	Dasatinib – not recommended. Nilotinib – recommended for Philadelphia-chromosome-positive CML if standard dose imatinib unsuccessful or unsuitable. Imatinib high dose – not recommended if disease has progressed after standard dose.	x		31/01/2012	0	LCNDG + CDF recommendation
Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)	31/12/2011	Tocilizumab – recommended if NSAIDs, steroids and methotrexate have failed.	x		17/01/2012	17	
Osteosarcoma - mifamurtide (TA235)	31/10/2011	Mifamurtide – recommended as a treatment for specified children, adolescents and young adults with osteosarcoma.	x		15/11/2011	15	
Acute coronary syndromes - ticagrelor (TA236)	31/10/2011	Ticagrelor – recommended combined with low-dose aspirin for up to a year as a treatment for specified people with acute coronary syndromes.	x		15/11/2011	15	To be used in conjunction with SLCSN guideline
Ankylosing spondylitis - golimumab (TA233)	31/08/2011	Golimumab – a recommended option for severe, active ankylosing spondylitis in the same circumstances as TA143 when NSAIDs unsuccessful.	x		20/09/2011	20	

Macular oedema (retinal vein occlusion) - dexamethasone (TA229)	31/07/2011	Dexamethasone intravitreal implant – recommended for specified people with macular oedema due to retinal vein occlusion.	x		16/08/2011	16	
Epilepsy (partial) - retigabine (adjuvant) (TA232)	31/07/2011	Retigabine – a recommended adjunctive option for partial onset seizures with or without secondary generalisation in some people with epilepsy.	x		16/08/2011	16	
Multiple myeloma (first line) - bortezomib and thalidomide (TA228)	31/07/2011	Thalidomide – a recommended option for specified people with multiple myeloma. Bortezomib – a recommended option only if thalidomide not tolerated or suitable.	x		31/07/2011	0	LCNDG + CDF recommendation
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)	31/07/2011	Bivalirudin – recommended as a possible treatment for adults with STEMI having percutaneous coronary intervention.	x		16/08/2011	16	
Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)	30/06/2011	Rituximab – recommended as a possible treatment to maintain remission.	x		30/06/2011	0	LCNDG + CDF recommendation
Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab (TA225)	30/06/2011	Golimumab – a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated.	x		19/07/2011	19	
Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate (TA223)	31/05/2011	Naftidrofuryl oxalate – a recommended option for intermittent claudication in peripheral arterial disease. Cilostazol, pentoxifylline and inositol nicotinate – not recommended.	x		21/06/2011	21	
Thrombocytopenic purpura - romiplostim (TA221)	30/04/2011	Romiplostim – recommended for specified people with chronic, severe, and refractory ITP.	x		17/05/2011	17	
Psoriatic arthritis - golimumab (TA220)	30/04/2011	Golimumab – recommended as a possible treatment after trying other DMARDs in the same circumstances as TA199.	x		17/05/2011	17	
			21	0			
			% "Yes"	% "N/A"	–		Average implement time (days)
Adherence statistics for 2011-12			100%	0%		17	